Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Korro Bio in a report released on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($6.83) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping analysts' consensus estimates of ($2.60) by $0.11. The company had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

Several other analysts have also issued reports on KRRO. Oppenheimer dropped their price objective on Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Royal Bank of Canada decreased their target price on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 19th. HC Wainwright lowered their target price on Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Chardan Capital reissued a "buy" rating and set a $25.00 price target on shares of Korro Bio in a report on Tuesday, May 13th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $102.43.

Korro Bio Stock Performance

NASDAQ KRRO traded up $1.00 during trading hours on Tuesday, hitting $15.85. 181,703 shares of the company traded hands, compared to its average volume of 110,206. The business's 50-day moving average is $14.62 and its 200-day moving average is $27.45. The stock has a market capitalization of $148.85 million, a price-to-earnings ratio of -1.68 and a beta of 2.45. Korro Bio has a twelve month low of $10.29 and a twelve month high of $98.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Korro Bio by 7.8% in the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock valued at $366,000 after purchasing an additional 691 shares in the last quarter. Bank of New York Mellon Corp increased its position in Korro Bio by 3.0% in the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company's stock valued at $563,000 after acquiring an additional 435 shares during the period. Raymond James Financial Inc. bought a new position in Korro Bio during the 4th quarter worth $394,000. AlphaQuest LLC boosted its holdings in Korro Bio by 23.2% in the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock valued at $83,000 after acquiring an additional 412 shares during the last quarter. Finally, Swiss National Bank bought a new stake in shares of Korro Bio in the 4th quarter valued at $381,000. Institutional investors and hedge funds own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).